Comparative in vitro metabolism of indinavir in primates - a unique stereoselective hydroxylation in monkey

References

• BALANI, S. K., ARISON, B. H., MATHAI, L., KAUFFMAN, L., MILLER, R. R., STERNS, R. A., CHEN, I.-W. and LIN, J. H., 1995, Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metabolism and Disposition, 23,266–270.
   Google Scholar
• CHAURET, N., GAUTHIER, A., MARTIN, J. and NICOLL -GRIFFITH, D. A., 1997, In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metabolism and Disposition, 25, 1130–1136.
   PubMed Web of Science ®Google Scholar
• CHIBA, M., HENSLEIGH, M. and LIN, J. H., 1997, Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochemical Pharmacology, 53, 1187–1195.
   PubMed Web of Science ®Google Scholar
• CHIBA, M., HENSLEIGH, M., NISHIME, J. A., BALANI, S. and LIN, J. H., 1996, Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metabolism and Disposition, 24, 307–314.
   PubMed Web of Science ®Google Scholar
• DUIGNAN, D. B., SIPES, I. G., CIACCIO, P. J. and HALPERT, J. R., 1988, The metabolism of xenobiotics and endogenous compounds by the constitutive dog liver cytochrome P450 PBD-2. Archives of Biochemistry and Biophysics, 267, 294–304.
   PubMed Web of Science ®Google Scholar
• EBERHART, D. C., GEMZIK, B., HALVORSON, M. R. and PARKINSON, A., 1991, Species differences in the toxicity and cytochrome P450 HIA-dependent metabolism of digitoxin. Molecular Pharmacology, 40, 859–867.
   PubMed Web of Science ®Google Scholar
• IGARASIR, T., SAKUMA, T., Isowd, M., NAGATA, R. and KAMATAKI, T., 1997, Marmoset liver cytochrome P450s: Study for expression and molecular cloning of their cDNAs. Archives of Biochemistry and Biophysics, 339, 85–91.
   PubMed Web of Science ®Google Scholar
• JACQZ-AIGRAIN, E., GUEGUEN, M., ZANGER, U. M., ROBIEUX, I. and ALVAREZ, F., 1991, Cytochrome P450I1D subfamily in non-human primates. Catalytical and immunological characterization. Biochemical Pharmacology, 41, 1657–1663.
   Google Scholar
• KAMINSKY, L. S., 1989, Warfarin as a probe of cytochrome P450 function. Drug Metabolism Reviews, 20, 479–487.
   PubMed Web of Science ®Google Scholar
• LADDISON, K. J., SPEIRS, A., MANKOWSKI, D. C., TWEEDIE, D. and LAWTON, M. P., 1995, Cloning, sequencing, and expression of the cynomolgus monkey liver cytochrome P450 that is orthologous to human CYP2D6. ISSX Proceedings, 8, 367.
   Google Scholar
• LIN, J. H., 1995, Species similarities and differences in pharmacokinetics. Drug Metabolism and Disposition, 23, 1008–1021.
   PubMed Web of Science ®Google Scholar
• LIN, J. H., CHB3A, M., BALANI, S. K., CHEN, I.-W., KWEI, G. Y.-S., VASTAG, K. J. and NISHIME, J. A., 1996, Species differences in the pharmacokinetics and metabolism of indinavir, a potent HIV protease inhibitor. Drug Metabolism and Disposition, 24, 1111–1120.
   Google Scholar
• LOWRY, O. H., ROSENBROUGH, N. J., FARR, A. L. and RANDAL, R. J., 1951, Protein measurement with Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• NIWA, T., KANEKO, H., NARTTOME, Y., TOGAWA, A., SHIRAGA, T., IWASAKI, K., TOZUKA, Z. and HATA, T., 1995, Species and sex differences of testosterone and nifedipine oxidation in liver microsomes of rat, dog and monkey. Xenobiotica, 25, 1041–1049.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide binding pigment of liver microsomes. journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• OTTON, S. V., TYNDALE, R. F., Wu, D., INABA, T., KALOW, W. and SELLERS, E. M., 1992, Catalytic and immunologic similarities between monkey and human liver cytochrome P-450dbl (human cytochrome P-450 2D6). Drug Metabolism and Disposition, 20, 1–5.
   PubMed Web of Science ®Google Scholar
• RING, B. J., PARLI, C. J., GEORGE, M. C. and WRIGHTON, S. A., 1994, In vitro metabolism of zatosetron. Interspecies comparison and role of CYP3A. Drug Metabolism and Disposition, 22, 352–357.
   PubMed Web of Science ®Google Scholar
• RODRIGUES, A. D., KUKULKA, M. J., FERRERO, J. L. and CASHMAN, J. R., 1995, In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal fiavin-containing monooxygenase-dependent stereoselective N'-oxidation. Drug Metabolism and Dis-position, 23, 1143–1152.
   PubMed Web of Science ®Google Scholar
• SHARER, J. E., SHIPLEY, L. A., VANDENBRANDEN, M. R., BINKLEY, S. N. and WRIGHTON, S. A., 1995, Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metabolism and Disposition, 23, 1231–1241.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., MIMURA, M., INOUE, K., NAKAMURA, S., ODA, H., OHMORI, S. and YAMAZAKI, H., 1997, Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkey, and human. Archives of Toxicology, 71, 401–408.
   PubMed Web of Science ®Google Scholar
• SHOU, M., KORZEKWA, K. R., KRAUSZ, K. W., CRFSPI, C. L., GONZALEZ, F. J. and GELBOM, H. V., 1994, Regio- and stereo-selective metabolism of phenanthrene by twelve cDNA-expressed human, rodent and rabbit cytochromes P-450. Cancer Letters, 83, 305–313.
   PubMed Web of Science ®Google Scholar
• SMITH, D. A., 1991, Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metabolism Reviews, 23, 355–373.
   PubMed Web of Science ®Google Scholar
• SMITH, G., MODI, S., PILLA I., LIAN, L.-Y., SUTCLIFFE, M. J., PRITCHARD, M. P., FRIEDBERG, T., ROBERTS, G. C. K. and WOLF, C. R., 1998, Determinants of the substrate specificity of human cytochrome P-450 CYP2D 6: design and construction of a mutant with testosterone hydroxyase activity. Biochemical Journal, 331, 783–792.
   Google Scholar
• STEVENS, J. C., SHIPLEY, L. A., CASHMAN, J. R., VANDERBRANDEN, M. and WRIGHTON, S. A., 1993, Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metabolism and Disposition, 21, 753–760.
   PubMed Web of Science ®Google Scholar
• VACCA, J. P., DORSEY, B. D., SCHLEIF, W. A., LEVIN, R. B., MCDANIEL, S. L., DARKE, P. L., ZUGAY, J., QUINTERO, J. C., BLAHY, O. M., ROTH, E., SARDANA, V., SCHLABACH, A. J., GRAHAM, P. I., CONDRA, J. H., GOTLIB, L., HOLLOWAY, M. K., LIN, J. H., CHEN, I.-W., VASTAG, K., OSTOVIC, D., ANDERSON, P. S., EMINI, E. A. and HUFF, J. R., 1994, L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proceedings of the National Academy of Sciences, USA, 91, 4096–4100.
   Google Scholar
• WAN, J., IMAOKA, S., CHOW, T., HIROI, T., YABUSAKI, Y. and FUNAE, Y., 1997, Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity. Archives of Biochemistry and Biophysics, 348, 383–390.
   PubMed Web of Science ®Google Scholar
• Wu, D., OTTON, V., MORROW, P., INABA, T., KALOW, W. and SELLERS, E. M., 1993, Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. Journal of Pharmacology and Experimental Therapeutics, 266, 715–719.
   PubMed Web of Science ®Google Scholar
• YASUMORI, T., CHEN, L., NAGATA, K., YAMAZOE, Y. and KATO, R., 1992, Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). Journalof Pharmacology and Experimental Therapeutics, 264, 89–94.
   Web of Science ®Google Scholar
• ZHAO, X. J. and IsffizAdu, T., 1997, The in vitro hepatic metabolism of quinidine in mice, rats and dogs: comparison with human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 283, 1168–1176.
   PubMed Web of Science ®Google Scholar